Aims-To review the results of 73 consecutive fine needle aspirations (FNAs) that were collected by a pathologist and analysed by immunoflow cytometry. Material for a cell block was also collected from some of these lesions. Methods-The setting was a large general hospital in rural New Zealand. The FNAs were performed by a pathologist, or a radiologist for image guided localisations. Material for immunoflow cytometry was collected into RPMI and, when required, material for a cell block was collected into formalin. In the past, the cytological diagnosis of lymphomas from fine needle aspiration (FNA) samples has been particularly diYcult. Usually, one obtains a sample that is either obviously malignant but equivocally lymphoid or, conversely, a sample that is obviously lymphoid but equivocally malignant. However, recently FNA diagnosis of lymphoid lesions has been made easier by the arrival of immunoflow cytometry in most large pathology laboratories. Immunoflow cytometry has been used mainly for the analysis of haematological diseases, but increasingly it is being used by cytologists. Early studies of FNAs and immunoflow cytometry used a limited range of antibodies and were not able to perform dual staining. Recently, there have been substantial advances in the sophistication of the methods and equipment used for flow cytometry. It is accepted that FNA cytology with immunolabelled flow cytometry can, in some circumstances, serve as a replacement for open biopsy and conventional histology and immunohistochemistry.
In the past, the cytological diagnosis of lymphomas from fine needle aspiration (FNA) samples has been particularly diYcult. Usually, one obtains a sample that is either obviously malignant but equivocally lymphoid or, conversely, a sample that is obviously lymphoid but equivocally malignant. However, recently FNA diagnosis of lymphoid lesions has been made easier by the arrival of immunoflow cytometry in most large pathology laboratories. Immunoflow cytometry has been used mainly for the analysis of haematological diseases, but increasingly it is being used by cytologists. Early studies of FNAs and immunoflow cytometry used a limited range of antibodies and were not able to perform dual staining. Recently, there have been substantial advances in the sophistication of the methods and equipment used for flow cytometry. It is accepted that FNA cytology with immunolabelled flow cytometry can, in some circumstances, serve as a replacement for open biopsy and conventional histology and immunohistochemistry.
1 2 However, FNA with immunoflow cytometry is not always successful. Scanty cellularity in the sample can prevent a satisfactory analysis, and even with an adequate sample the results might be misleading. In particular, non-lymphoid malignancies can be hard to distinguish from lymphoid lesions if the sample also contains reactive lymphoid cells; B cell lymphomas sometimes do not exhibit light chain restriction; and T cell lymphomas can have a large population of reactive B cells.
The aim of our study was to review the results of 73 consecutive FNAs that were collected by a pathologist and analysed by immunoflow cytometry. Material for a cell block was also collected from some of these lesions. The setting was a large general hospital in rural New Zealand. The FNAs were performed over a two year period. In this time, approximately 800 FNAs of non-breast lesions were performed together with approximately 1400 breast FNAs. which case one of these pathologists prepared the slides after the radiologist had aspirated the lesion. The FNAs performed by the pathologists were done with a needle only technique, using a 23 or 25 gauge 1.25 inch (3 cm) needle. The slides were air dried, often aided by a small hair dryer, and DiV-Quik ® stained (Dade Behring Diagnostics, Newmarket, Auckland, New Zealand). The slides were then examined with a portable Olympus CHK microscope and a hand written report was issued within a few minutes. If this examination of the specimen suggested that the lesion might be lymphoid and lymphoma seemed possible, then a second FNA was performed, still using a needle only technique, to collect a second sample. This sample was collected quickly and the needle was washed through with 3 ml of heparin RPMI (12.8 mg of heparin ammonium in 45 ml of RPMI) within a few seconds of being collected. The reason for the urgency was that a clotted sample reduces the yield of cells for flow cytometry. Early in our experience with collecting specimens for flow cytometry we washed needles through with sterile heparin saline before the FNA was performed, but we found that this was not necessary. The slides were taken back to the laboratory to be mounted and examined again. The specimen in RPMI was taken to the haematology laboratory, transferred to a 5 ml tube and centrifuged for two minutes at approximately 400 ×g. The supernatant was discarded and the cells were resuspended in 2 ml of ammonium chloride lysis solution. The cells were gently vortexed, incubated at room temperature for 10 minutes, and then centrifuged again for two minutes. The leucocytes were then resuspended in 2 ml of phosphate buVered saline (PBS). If debris was present, it was removed with a nylon Swiss screen filter. An approximate cell count was performed and a panel of directly conjugated monoclonal antibodies was selected (table 1) (Immunotech Inc, Westbrook, Maine, USA). The cells and the antibodies were incubated for 20 minutes in the dark at room temperature. These were then washed once in PBS, spun down, and then washed again. They were then analysed with the flow cytometer. Material for and light chain analysis was treated diVerently. The centrifuged sample in RPMI was incubated with prewarmed PBS for 20-30 minutes at 37°C, to remove the cytophilic immunoglobulin, and then centrifuged. The supernatant was discarded and if red blood cells were present they were lysed with ammonium chloride as above. Cells were then incubated with antibodies (against CD19/ light chain or CD19/ light chain) as above.
The "first run" panel of antibodies evolved as our experience developed and with the acquisition of a new immunoflow cytometer approximately half way through our study. At the start of the study, a Coulter PROFILE II was used but later the laboratory obtained a Coulter EPICS ® XL (Beckman Coulter Inc, Fullerton, California, USA). In some cases we performed a "second run" with a more specialised panel to investigate a specific diagnosis. The panel of antibodies used was sometimes restricted by the scarcity of cells. In these cases, antibodies against CD19/ light chain and CD19/ light chain were given priority.
In our laboratory we have adopted light chain ratio limits from previous studies. [2] [3] [4] A to ratio of greater than 3 or a to ratio of greater than 2 was accepted as evidence of monoclonality.
For some cases, cell blocks for immunohistochemistry were collected as described previously. 5 These were usually taken after the initial FNA showed overtly malignant cytology but it was not certain that the lesion was lymphoid in nature. Table 2 shows our results-the cases are set in chronological order within each diagnostic category. It can be seen that the range of cell markers expanded during the course of our study. The panel of markers was sometimes tailored a little in view of the initial diagnosis, so as to focus on a particular issue and to avoid wasting cells.
Results

Discussion
Nine of the 73 samples (12%) had inadequate cells for analysis. Four of these were from benign lymph nodes. It was felt that adequate samples were easier to obtain from malignant lesions simply because of their larger size. Young et al found that five of 107 (4.7%) of their specimens were inadequate in a similar study.
2 A highly cellular lymphoma aspirate might exhibit uniform negativity on immunoflow cytometry if the cells are necrotic, as in case 3.
Twenty eight cases exhibited light chain restriction (defined above), allowing an unequivocal diagnosis of B cell lymphoma to be made on the FNA sample alone. On review of the notes at the end of our study, we could find no evidence that any of these diagnoses were incorrect. Case 48 had been thought to be suspicious of lymphoma with a to ratio of 1.95. However, a review of the notes about a year after the FNA was performed revealed no clear evidence that the patient had developed lymphoma. In particular, there was no evidence of lymphoma on a computed tomography scan. Case 73 also had a marginal light chain ratio but did not have clinically evident lymphoma eight months later.
Five of the 33 B cell lymphomas did not exhibit light chain restriction. For three case this was because of inadequate cellularity. The other two (cases 9 and 33) were particularly confusing because the cytology showed a malignant tumour with highly atypical cells mixed with benign looking lymphoid cells. The flow cytometry showed no evidence of light chain restriction. Biopsies were taken and the flow cytometry results from these were similar to those from the FNA. However, paraYn wax embedded sections and immunohistochemistry showed that the large highly atypical cells were CD45 and CD20 positive and negative for cytokeratin, S100, and CD3. Thus, a diagnosis of T cell rich B cell lymphoma was made. We assumed that the neoplastic B cells were not expressing light chains strongly or were "swamped" by a population of reactive B cells. Except for cases 9 and 33, the lowest light chain ratio of any B cell lymphoma was a to ratio of 3.1 (case 16). Case 37 was remarkable in that it showed artefactual light chain restriction in a T cell lymphoma (fig 1) . We assume that this was as a result of specific binding of to the surface of the tumour cells, perhaps as an autoimmune response to the tumour cells. The lymphoma occurred in a patient with AIDS. On biopsy, the tumours cells were strongly positive for CD3 but negative for CD20. Fortunately, this artefact did not confuse the diagnosis, because coexpression of light chain with CD19 was not found. For 18 cases it was possible to make a diagnosis of B cell lymphoma and also subtype the lymphoma as either CLL (chronic lymphocytic leukaemia/small lymphocytic lymphoma), FCCL (follicle centre cell lymphoma), or mantle cell lymphoma. Most of the other cases that exhibited light chain restriction were called "B cell lymphoma, exact type uncertain" or "diVuse large B cell lymphoma" if they were composed of overtly malignant large cells. Uncertainty as to the exact type of B cell lymphoma was not considered suYcient reason to perform a biopsy. This was usually because the patient had other medical problems that were a more immediate risk to the patient's health or because exact typing would not alter treatment.
Four of the six T cell lymphomas were diagnosed with a combination of cytology, flow cytometry, and cell block immunohistochemistry, but for two it was not possible to collect a cell block. Both of these then had biopsies. The participation of the pathologist in the collection of the specimen and the immediate assessment of the cytology meant that the need for cell block histology had been anticipated. The ratio of CD4 to CD8 (or CD8 to CD4) was examined but this was not usually useful in the recognition of T cell lymphoma. The benign lesions in cases 59 and 65 had CD4 to CD8 ratios of 4.15 and 4.29, respectively. Only two of the six T cell lymphomas had CD4 to CD8 (or CD8 to CD4) ratios greater than these. Jeffers et al describe one case of T cell lymphoma in their series of 46 FNA sampled lesions. 6 This lymphoma showed subset restriction, with more than 90% of T cells expressing CD8. Coexpression of CD4 and CD8 was examined for four of the six T cell lymphomas but was only found in case 34. Loss of pan-T cell anti- with the aid of cell block immunohistochemistry. We advocate the use of cell block immunohistochemistry in preference to immunoflow cytometry for cases in which the cytological appearance of the specimen is overtly malignant but the diVerential diagnosis includes non-lymphoid malignancy.
